BioNTech SE in the news

Berenberg increased its price target for BioNTech stock to $140 following promising oncology data, despite the company reporting a significant net loss in Q2 2026.

BioNTech CEO Ugur Sahin sold a total of 93,000 ordinary shares in early October 2026, according to a pre-established trading plan.

BioNTech's stock declined, trading at USD 95.73 on October 6, 2026, despite analyst 'Buy' ratings and price targets, following a significant revenue drop and restructuring efforts, with its next earnings report due November 3, 2026.

BioNTech SE's stock increased after-hours on October 5, 2026, while the company plans to close three German production sites and reported positive Phase 3 data for Gotistobart.

Analysts recommend buying BioNTech stock with an average price target of  136.33, indicating a 40.69% upside.

BioNTech stock has a "Moderate Buy" consensus at a USD 126 target, despite a recent quarterly loss, and its future hinges on its oncology pipeline.

BioNTech is undergoing major changes, including the departure of two founders to start a new company, the closure of three German production sites, ongoing mRNA patent lawsuits, and executive share sales.

BioNTech SE is shifting its focus to an oncology pipeline with 33 trials and $19 billion in cash, with pivotal data for its key drug expected after 2028.

BioNTech is closing three German sites, reported updated positive trial data for gotistobart, and its stock traded at EUR 86.10 over the weekend.

BioNTech experienced a significant 59.5% Q2 2026 revenue decline and a loss per share of USD 2.53, yet analysts maintain a "Moderate Buy" consensus with a target price of USD 126.00.

BioNTech and OncoC4 released updated Gotistobart data from their Phase 3 study, showing an improved median overall survival of 18.5 months.

BioNTech plans to close three plants and cut 1,800 jobs, a move questioned by Tübingen's mayor who suggests the closures were premeditated.

Discussions surrounding BioNTech's stock are centered on its potential restructuring, the future of personalized mRNA therapies, and the need for solid clinical data, following a slight weekly stock decline.

BioNTech's stock ranking declined in a boerse.de investment universe managed by an AI-powered trend-following advisor.

BioNTech's CEO sold 34,000 shares in early October via a pre-planned trading arrangement.

Morgan Stanley set a USD 115 target for BioNTech stock following positive oncology data from a Phase 3 trial, despite a decrease in Q2 revenue and an increased net loss.

BioNTech stock decreased by 0.12 percent to EUR 86.05 in after-hours trading on October 2, 2026.

BioNTech SE develops and commercializes immunotherapies, including an mRNA vaccine for SARS-CoV-2 and a broad pipeline of oncology and infectious disease drugs.

This article discusses Volatus Aerospace's advancements in drone technology and a new government contract, BioNTech's strategic site closures to refocus on oncology, and Micron Technology's record-breaking financial performance driven by AI infrastructure.

BioNTech founders are departing to start a new company, causing uncertainty among investors and criticism over the lack of transparency and potential conflicts of interest.